The Tumor Microenvironment in Classic Hodgkin’s Lymphoma in Responder and No-Responder Patients to First Line ABVD Therapy
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Tumor Microenvironment in Classic Hodgkin’s Lymphoma in Responder and No-Responder Patients to First Line ABVD Therapy
Authors
Keywords
-
Journal
Cancers
Volume 15, Issue 10, Pages 2803
Publisher
MDPI AG
Online
2023-05-18
DOI
10.3390/cancers15102803
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Classic Hodgkin Lymphoma Refractory for ABVD Treatment Is Characterized by Pathologically Activated Signal Transduction Pathways as Revealed by Proteomic Profiling
- (2022) Bent Honoré et al. Cancers
- NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022
- (2022) Richard T. Hoppe et al. Journal of the National Comprehensive Cancer Network
- The Hodgkin Lymphoma Immune Microenvironment: Turning Bad News into Good
- (2022) Victoria Menéndez et al. Cancers
- The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms
- (2022) Rita Alaggio et al. LEUKEMIA
- Updates in the Role of Checkpoint Inhibitor Immunotherapy in Classical Hodgkin’s Lymphoma
- (2022) Shazia Nakhoda et al. Cancers
- Tumor Microenvironment and Microvascular Density in Human Glioblastoma
- (2022) Roberto Tamma et al. Cells
- Differential P-Glycoprotein/CD31 Expression as Markers of Vascular Co-Option in Primary Central Nervous System Tumors
- (2022) Tiziana Annese et al. Diagnostics
- Nivolumab discontinuation and retreatment in patients with relapsed or refractory Hodgkin lymphoma
- (2021) Liudmila V. Fedorova et al. ANNALS OF HEMATOLOGY
- Tumor Cell Microenvironment and Microvessel Density Analysis in MALT Type Lymphoma
- (2021) ROBERTO TAMMA et al. ANTICANCER RESEARCH
- CD68-positive tumour associated macrophages, PD-L1 expression, and EBV latent infection in a high HIV-prevalent South African cohort of Hodgkin lymphoma patients
- (2021) Katherine Antel et al. PATHOLOGY
- Different spatial distribution of inflammatory cells in the tumor microenvironment of ABC and GBC subgroups of diffuse large B cell lymphoma
- (2021) Diego Guidolin et al. CLINICAL AND EXPERIMENTAL MEDICINE
- Correlation between circulating blood and microenvironment T lymphocytes in diffuse large B-cell lymphomas
- (2021) Filomena Emanuela Laddaga et al. JOURNAL OF CLINICAL PATHOLOGY
- NIVOLUMAB FOR RELAPSED OR REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL) AFTER AUTOLOGOUS TRANSPLANTATION: 5‐YEAR OVERALL SURVIVAL FROM THE PHASE 2 CHECKMATE 205 STUDY
- (2021) S. M. Ansell et al. HEMATOLOGICAL ONCOLOGY
- The PD-1/PD-L1 Checkpoint in Normal Germinal Centers and Diffuse Large B-Cell Lymphomas
- (2021) Marcos Garcia-Lacarte et al. Cancers
- Low Density of CD3+ Tumor-Infiltrating Lymphocytes Is Predictive of a Poor Prognosis in Diffuse Large B-Cell Lymphoma Independently of MYC and BCL2 Double Expression Status: A Potential Utility of Immunoscore Based on Whole-Slide Image Analysis
- (2021) Bogyeong Han et al. BLOOD
- Five-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL)
- (2021) Philippe Armand et al. BLOOD
- Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis
- (2021) Yuqin Song et al. CLINICAL CANCER RESEARCH
- Hodgkin Lymphoma: A Special Microenvironment
- (2021) Giuseppina Opinto et al. Journal of Clinical Medicine
- Immunosuppressive Microenvironment and Efficacy of PD-1 Inhibitors in Relapsed/Refractory Classic Hodgkin Lymphoma: Checkpoint Molecules Landscape and Macrophage Populations
- (2021) Artem Gusak et al. Cancers
- The role of CD68+ macrophage in classical Hodgkin lymphoma patients from Egypt
- (2020) Osama Mohamed et al. Diagnostic Pathology
- Low‐dose pembrolizumab and nivolumab were efficacious and safe in relapsed and refractory classical Hodgkin lymphoma: experience in a resource‐constrained setting
- (2020) Thomas S.Y. Chan et al. HEMATOLOGICAL ONCOLOGY
- Tumor-associated macrophages in classical Hodgkin lymphoma: hormetic relationship to outcome
- (2020) Laura Werner et al. Scientific Reports
- Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial
- (2020) Catherine S Diefenbach et al. Lancet Haematology
- Hodgkin Reed–Sternberg-Like Cells in Non-Hodgkin Lymphoma
- (2020) Paola Parente et al. Diagnostics
- STAT3, tumor microenvironment, and microvessel density in diffuse large B cell lymphomas
- (2019) Roberto Tamma et al. LEUKEMIA & LYMPHOMA
- Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management
- (2018) Stephen M. Ansell AMERICAN JOURNAL OF HEMATOLOGY
- Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
- (2018) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Intratumoral infiltrating lymphocytes correlate with improved survival in colorectal cancer patients: Independent of oncogenetic features
- (2018) Ehsan Nazemalhosseini-Mojarad et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Macrophages in the microenvironment of head and neck cancer: potential targets for cancer therapy
- (2018) Diane Evrard et al. ORAL ONCOLOGY
- Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma
- (2017) Robert Chen et al. JOURNAL OF CLINICAL ONCOLOGY
- Role of mast cells in fibrosis of classical Hodgkin lymphoma
- (2016) Shoko Nakayama et al. INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY
- The number of tumor infiltrating T-cell subsets in lymph nodes from patients with Hodgkin lymphoma is associated with the outcome after first line ABVD therapy
- (2016) Sara Alonso-Álvarez et al. LEUKEMIA & LYMPHOMA
- The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation
- (2016) Kankana Bardhan et al. Frontiers in Immunology
- Tumour-associated macrophages correlate with poor prognosis in myxoid liposarcoma and promote cell motility and invasion via the HB-EGF-EGFR-PI3K/Akt pathways
- (2015) A Nabeshima et al. BRITISH JOURNAL OF CANCER
- The role of indoleamine 2,3-dioxygenase (IDO) in immune tolerance: Focus on macrophage polarization of THP-1 cells
- (2014) Xian-Feng Wang et al. CELLULAR IMMUNOLOGY
- Treatment of Hodgkin Lymphoma: A 50-Year Perspective
- (2014) George P. Canellos et al. JOURNAL OF CLINICAL ONCOLOGY
- CD68-positive tumor-associated macrophages predict unfavorable treatment outcomes in classical Hodgkin lymphoma in correlation with interim fluorodeoxyglucose-positron emission tomography assessment
- (2014) Mohamed Touati et al. LEUKEMIA & LYMPHOMA
- CD163 Expression Was Associated with Angiogenesis and Shortened Survival in Patients with Uniformly Treated Classical Hodgkin Lymphoma
- (2014) Young Wha Koh et al. PLoS One
- The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies
- (2013) Li Shi et al. Journal of Hematology & Oncology
- The microenvironment in classical Hodgkin lymphoma: An actively shaped and essential tumor component
- (2013) Yuxuan Liu et al. SEMINARS IN CANCER BIOLOGY
- Tumour-infiltrating macrophages and clinical outcome in breast cancer
- (2011) S M A Mahmoud et al. JOURNAL OF CLINICAL PATHOLOGY
- Immunosuppressive CD14+HLA-DRlow/- monocytes in B-cell non-Hodgkin lymphoma
- (2010) Y. Lin et al. BLOOD
- The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape
- (2010) Donatella Aldinucci et al. JOURNAL OF PATHOLOGY
- Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma
- (2010) Christian Steidl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma
- (2009) Alison J. Moskowitz et al. BRITISH JOURNAL OF HAEMATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started